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Abstract Pertussis epidemiology was examined in selected
Central and Eastern European countries andTurkey (CEEs)
from 1945 to 2005. Epidemiology and immunisation cov-
erage data were collected fromNational Health Departments
and Epidemiology Institutes. Pertussis diagnosis was made
by the World Health Organization (WHO) clinical criteria,
laboratory confirmation and/or epidemiological link, except
for Romania (WHO clinical case definition used). In the
pre-vaccine era, pertussis incidence (except Turkey)
exceeded 200/100,000 (range180–651/100,000), with 60-
70% of cases occurring in pre-school children. Until 2007,
a second-year booster was givenin Estonia, Lithuania and
Turkey, and an additional pre-school booster elsewhere.
During 1995–2005, immunisation coverage by the age of 2
years exceeded 80% (range 80–98%) and, excluding
Estonia, pertussis incidence was <3/100,000. Age-specific
incidence rates rose in 5–14 year olds in Poland, Estonia
and the Czech Republic. Incidence rates in children <1 year
of age remained unchanged. There were two age distribu-
tion patterns. In the Czech Republic and Estonia, 16% of
cases occurred in pre-school children and 17% and 22% in
children >15 years of age, respectively; in Romania, Turkey
and Lithuania, 51%, 71% and 73%, respectively, occurred
in pre-school children and <7% in children aged >15 years.
Pertussis infection persists, despite high immunisation
coverage. Compared with the pre-vaccine era, the age
distribution changed differentially in CEEs, with an
apparent shift towards older children.
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Introduction
Approaches to pertussis diagnosis, surveillance and immu-
nisation vary widely across Europe. However, most
countries have reported high levels of vaccine coverage in
infants and toddlers, and significant reductions in infant
morbidity and mortality have been achieved [19]. Although
the absolute incidence of pertussis has substantially
decreased due to the effective protection of infants and
toddlers, the relative proportion of older age groups with
pertussis, adolescents and adults in particular, has recently
increased in several countries, including Europe, the United
States (USA) and Canada [2, 5, 8, 12, 19]. A substantial
disease burden also persists in these countries amongst
infants too young to be fully vaccinated [5, 8]. In Sweden,
the overall disease rates in very young infants fell after the
introduction of routine pertussis vaccination. However,
since 2001, the disease rates in this group remain higher
than in any other age group [6].
The epidemiology of pertussis in Western European
countries was recently reviewed by Celentano et al. [1],
who noted that pertussis is still an endemic disease in most
countries and that, between 1998 and 2002, the reported
incidence rates in the >14 years old age group increased by
115%. A comparison of pertussis surveillance systems in
European countries has recommended that the World Health
Organization (WHO) case definition, the standardisation of
laboratory diagnosis and the integration of information on
deaths from alternative sources should be supported [16].
However, the epidemiology of pertussis in Eastern Europe
has, thus far, been reported only on an individual country
basis [7, 15].
This report is based on pertussis epidemiology and the
data presented by countries present at a meeting of the
Central European Vaccination Advisory Group (CEVAG)
which took place in Bucharest, Romania, in March 2006.
The CEVAG was established in 2005 to address issues
relating to the impact, control and prevention of vaccine-
preventable diseases in Central Europe [3]. Its members
include vaccinologists, epidemiologists and paediatricians.
We describe pertussis epidemiology and vaccination cover-
age rates in selected Central and Eastern European
countries and Turkey (CEEs) from 1945 to 2005 obtained
through a retrospective review of existing data sources in
the National Health Departments and Epidemiology Insti-
tutes of selected CEE countries.
Materials and methods
Data sources
A structured request for data was sent to CEVAG members
from each country to gather as close to a uniform set of data
as possible from each country. These data were presented at
the CEVAG meeting in March 2006. The countries included
in this analysis were: Estonia, Lithuania, Poland, the Czech
Republic, Romania and Turkey. The national surveillance
systems in all of the participating countries collected case-
based information on pertussis through statutory notifications
by medical practitioners, and covered all ages.
In Estonia, the data were retrieved from the Health
Protection Inspectorate; the reporting of suspected and/or
confirmed pertussis cases has been mandatory since 1945.
In Lithuania, the data were retrieved from the Centre of the
Communicable Diseases Prevention and Control and in
Poland from the National Register of Infectious Disease
maintained by Sanitary Inspection.
In the Czech Republic, the data were accessed from the
National Institute of Public Health. In the Czech Republic,
pertussis reporting was mandatory only from institutional care
facilities. Surveillance tools have altered periodically since
1945 (the Information System on Communicable Diseases
[ISPO] between 1982 and 1992, and EPIDAT from 1993 to
the present). However, in all systems, local reports of pertussis
disease were provided to the district level, district level to
regional level and from regional to national level.
The data in Romania were collected from the Romanian
Ministry of Public Health. Surveillance is conducted by the
National Surveillance Programme for Pertussis and the
Cantacuzino Institute—National Reference Centre for Pertus-
sis. Romanian health legislation requires mandatory hospital
admission for all paediatric pertussis cases (suspected or
confirmed).
In Turkey, the data were accessed from the Turkish
Ministry of Health. Reports of pertussis disease were
required to be reported to the Department of Health office
in every district by a phone service available 24 hours a
day. A case investigation form was to be completed in
every case and clinical samples were sent to the reference
microbiology laboratory for culture.
The following data are presented from 1945 through 2005:
total yearly incidence rates, age-specific incidence rates,
mortality rates, age distribution and the percentage of children
immunised with three doses of diphtheria-tetanus-pertussis
(whole-cell or acellular) (DTP) vaccine by the age of two years.
Case definition
The WHO clinical case definition for pertussis was used in
all countries, defined as a case diagnosed as pertussis by a
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physician or a person with a cough lasting at least two
weeks with at least one of the following symptoms: parox-
ysms of coughing, inspiratory whooping or post-tussive
vomiting without other apparent cause [20]. In addition, in
all countries except Romania, laboratory confirmation and/
or epidemiological link with a confirmed case was also
required. The available laboratory tests included culture,
serology (except Turkey) and, more recently, polymerase
chain reaction (PCR) (Estonia, Czech Republic, Turkey).
Details of the serology tests used in each laboratory over
time were not available in full. In Estonia and Lithuania,
the serological confirmation of pertussis disease is defined
as pertussis toxin (PT) IgA or IgM levels >12 EU (enzyme-
linked immunosorbent assay [ELISA] units) or a four-fold
increase in paired sera collected 10–14 days apart. In the
Czech Republic, pertussis disease cases were confirmed by
positive IgG PT in paired samples. In Poland, cases were
confirmed by elevated PT IgA. In Romania, tests for
specific antibodies against pertussis used agglutination and
complement fixing reactions.
Data analysis
The median incidence and mortality rates per 100,000
population were calculated for the following periods: pre-
or early vaccine era (1945–1960) and then 1961–1975 (era
characterised by widespread vaccination in most countries),
1976–1990 (era when vaccination in the former Soviet
Union became unpopular and the rates dropped dramati-
cally) and 1991–2005 (post-Soviet Union era). The follow-
ing age categories were considered for the analysis: <1
years, 1–4 years, 5–9 years, 10–14 years and ≥15 years.
Pertussis vaccines and vaccination schedules
The immunisation schedules and type of vaccines used
(whole-cell versus acellular) were obtained from National
Public Health Departments, Epidemiology Institutes and/or
from vaccine wholesalers in the participating countries.
Results
Recent vaccination schedules for the countries studied are
presented in Table 1. In all countries, acellular vaccines
were available on the private market. Data obtained from
each country on the primary vaccination coverage rates by
the age of two years available from 1991 onwards are
presented in Table 2. These data are consistent with DTP3
coverage reported by the WHO [21]. The overall incidence
rates for pertussis infections in the countries studied from
1945 to 2005 are shown in Fig. 1.
With the exception of Turkey, almost half of all pertussis
cases occurred in school-aged children in all countries,
Table 1 Immunisation schedule by country in 2005
Year when immunisation
was initiated
Primary immunisation First booster **Second booster
Estonia 1957 3 m, 4.5 m, 6 m 24 m -
Poland 1960 6 w, 12 w, 18 w 18 m *6y
Lithuania 1956 2 m, 4 m, 6 m 18 m -
Romania 1961 2 m, 4 m, 6 m 12 m 30–35 m
Czech Republic 1958 3 m, 4 m, 5 m 18–20 m *5y
Turkey 1968 2 m, 3 m, 4 m 16–24 m -
*Whole-cell vaccines were used in most countries except at the age points marked with asterisks, where acellular vaccines were used
**A second booster was given in Poland from 2004, in Romania from 1961 and in the Czech Republic at the age of 6 years between 1958 and
1994 and at the age of 5 years from 1995
Table 2 Percentage of children immunised (IR) at the age of two and the incidence (Inc) of pertussis per 100,000 population in the period
1991–2005
Estonia Poland Lithuania Romania Czech Republic Turkey
IR (%) Inc IR (%) Inc IR (%) Inc IR (%) Inc IR (%) Inc IR (%) Inc
1991–1995 77 12.0 94 1.4 83 6.8 98 4 99 0.3 78 0.7
1996–2000 88 23.0 97 5.9 93 2.5 98 1 98 1.1 80 0.8
2001–2005 94 23.3 98 5.3 94 1.4 97 0.7 98 3.4 83 0.3
Median 88 16.2 98 5.1 93 2.5 98 1.5 98 1.1 80 0.6
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irrespective of whether a second booster was used or not.
No correlation was noted between the age distribution of
pertussis infection and the use of a school entry pertussis
booster vaccination.
Czech Republic
Vaccination against pertussis began in the Czech Republic in
1958. TetrACT-HIB™ (Sanofi Pasteur, Lyon, France) is used
for primary vaccination and the first booster dose, whereas the
second booster dose is given using acellular vaccines.
Consistently high levels of vaccine coverage have been
achieved (Table 2). Incidence rates (data available from
1990) were low (<1/100,000, Fig. 1) until 1994, when an
increase was observed affecting the 5 to 14 year old age group
(Fig. 2). The incidence rates remained unchanged in infants
aged <1 year. Between 1991 and 2005, the highest proportion
of cases was observed in individuals >15 years of age (Fig. 3).
Estonia
Vaccination against pertussis began in Estonia in 1957, with
increasing vaccine coverage over the last 15 years (Table 2).
The whole-cell vaccines produced in the Research Institutes
of Moscow were used from 1957 to 1965, an adsorbed
DTPw vaccine (produced in the Soviet Union) from 1966 to
1991 and TetrACT-HIB™ has been in use since 1992. Over
the years, the immunisation schedule has been similar to that
presented in Table 1, except for the second booster that was
given at school entry from 1964 to 1980. An increase in the
total pertussis incidence was observed during this period in
Estonia following a steady decrease in pertussis observed
prior to 1991 (Fig. 1). Between 1991 and 2005, the overall
incidence rate of pertussis was between 12.0 and 23.3 per
100,000 population, which is considerably higher than the
rates observed in other countries (Table 2). The mortality rate
in the pre-vaccine era was 0.5 per 100,000 population. No
deaths were reported between 1991 and 2005. Age-specific
pertussis disease incidence rates for Estonia over the last 15
years showed a consistent increase in incidence rates for the
between 5 and 14 years old age group, while the incidence
rates in <1 year olds remained unchanged (Fig. 2). A clear
shift was seen over time towards a higher ratio of cases in
older age groups (Fig. 4) [11], with nearly 20% of cases
occurring in those >15 years of age (Fig. 3).
Lithuania
Vaccination against pertussis began in Lithuania in 1956.
Whole-cell vaccine (TetrACT-HIB™) is used for primary
and booster doses. Over the last 15 years, the vaccination
rates have increased in Lithuania (Table 2), while pertussis
disease incidence decreased progressively between 1945
and 2005 (Fig. 1). The age distribution data for pertussis
infection available from 1991 to 2005 showed that, in
Lithuania, the majority of pertussis cases occurred in
infants <1 year of age, with minimal pertussis reported
in subjects >15 years of age (Fig. 3).
Poland
Vaccination against pertussis began in Poland in 1960.
Primary vaccination doses and the first booster dose are
provided using adsorbed DTP vaccine, IBSS Biomed
(Krakow, Poland) (Table 1). The second booster is provided
using acellular vaccines. In the last 15 years, pertussis
incidence increased (Fig. 1), mainly in the 5 to 14 year old
age group (Fig. 2). The incidence among infants remained
unchanged. However, the highest number of cases contin-
ued to occur at age <1 year (Fig. 3). The mortality rate in
the pre-vaccine era was 2.3 per 100,000 in Poland. During


















































































Fig. 1 Incidence of pertussis in
various countries from 1945 to
2005
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Fig. 2 Age-dependent
incidence of pertussis infection
in the Czech Republic during
the period 1993–2005 (A),
Estonia 1991–2005 (B) and
Poland 1990–2003 (C)
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Romania
Vaccination against pertussis began in Romania in 1961.
DT COQ™ (Sanofi Pasteur, France) and Tritanrix™ HepB
(GlaxoSmithKline Biologicals, Rixensart, Belgium) are
used for the primary and booster doses in Romania.
Vaccination coverage rates have remained largely un-
changed over time (Table 2). Prior to the introduction of
immunisation, the median pertussis incidence rate reached
650/100,000 (Fig. 1), with a mortality of 4.85 per 100,000
population. A steady reduction in incidence rates was
observed over the next four decades. Pertussis mortality in
Romania between 1991 and 2005 did not exceed 0.01/
100,000. The age distribution of pertussis disease has
remained constant. The highest number of cases occurred
at age <1 year (Fig. 3).
Turkey
Vaccination against pertussis began in Turkey in 1968. DTP
vaccine adsorbed (Serum Institute of India, Pune, India) is
used for the primary and booster doses. Vaccination
coverage remained constant (78% to 83%) between 1991
and 2005. Pertussis incidence in the pre-vaccine era was
lower in Turkey than the other countries described above
(Fig. 1). However, a steady decline in the incidence rates
after the introduction of vaccination was similarly observed.
During the last 15 years, the median mortality rate in
Turkey was 0.002 per 100,000. No change in the age
distribution of cases has been observed in the last 15 years.
The highest number of cases occurred in infants age <1
year (Fig. 3).
Discussion
To our knowledge, this is the first review on the epidemiology
of pertussis in selected Central and Eastern European countries
over the last 60 years, a time during which these countries
underwent major economical and political changes. This
review has highlighted that, with the introduction of immuni-
sation in the late 1950s and early 1960s, the incidence of
pertussis has dropped significantly and mortality has become
almost non-existent in CEEs. However, in the last 15 years, in
some countries (e.g. Estonia and Poland), pertussis incidence
has increased in a similar fashion to the increases noted in the
USA [5, 9], with the age distribution of pertussis infection
apparently shifting towards older children. Although not
observed in our study, a similar increase affecting adolescents
has also been reported recently in Turkey [4].
Similarly to results from a review of pertussis epidemi-
ology conducted in Western Europe, the incidence rates of
pertussis observed in the countries presented in this report
were variable: they were higher in most Northern countries,
particularly in Estonia, while lower rates were observed in
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Fig. 3 Proportion (%) of
various age groups among per-
tussis patients in different
countries in 1991–2005. aFor
Lithuania, the percentages are
given for the 3–6 years old
(24.9%) and 7–14 years old
(27.6%) age groups. bRepresents
age <2 years. The other age
groups were not done
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A significant limitation of this review is its retrospective
nature. Data were collected from national registration
systems into which primary care physicians reported
pertussis cases, but the completeness of such data is not
systematically checked. Furthermore, although pertussis
cases with serological confirmation were included in the
analysis for all countries except Turkey, the details of the
serological tests and cut-offs used during the 60 years of
the study were not available in full.
Another important limitation of the study is that of per-
tussis under diagnosis and under reporting. Under diagnosis
and under reporting probably arise from both incomplete use
of bacterial culture techniques and PCR by primary care
physicians and, we expect, by a considerable degree of under
reporting in the older age groups, in whom pertussis is less
likely to be considered as a possible cause of cough illness.
This hypothesis is supported by evidence from Turkey
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Fig. 4 Age distribution of
pertussis patients from 1948 to
2004 in Estonia. A Age as a
proportion of all pertussis cases.
B Rate per 100,000 population
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antibodies against pertussis were present only in 1/3 of
subjects at the age of 0–73 months, while from 12 to 17
years of age, almost all subjects had anti-PT and anti-FHA
antibodies, despite the fact that no second pertussis booster
was given [10, 17]. Such high seroprevalence rates among
adolescents indicate widespread natural contacts with
Bordetella pertussis and suggest that the incidence rates
of pertussis in Turkey are much higher than that reported in
the national surveillance system and, thus, those presented
here. A study conducted in Lithuania also suggested that
pertussis infection is more common in older age groups
than has been officially reported [13]. The under reporting
of pertussis among adolescents and adults in the USA was
confirmed by another recent study reporting an incidence
rate of approximately 1% in this population, which is much
higher than that reported here [18].
National programmes for primary immunisation in all of
the countries presented in this review provide whole-cell
pertussis vaccines. However, over the last decade, the
introduction of acellular vaccines on the private markets has
occurred. The size of the latter is not fully characterised but,
according to the wholesale figures of 2005 in Estonia and
the Czech Republic, up to 1/4 of infants have been
immunised with acellular vaccines. In 2007, acellular
vaccines have been introduced into the national programme
in Lithuania and in the Czech Republic.
Although the introduction of immunisation programmes
clearly resulted in a drop in morbidity rates in all countries
(except Turkey, in which reporting problems may have pre-
dated vaccine introduction [personal communication from
the Turkish Ministry of Health]), we were unable to
demonstrate any correlation between the primary immuni-
sation rates and the overall incidence of pertussis. There are
several reasons for this. Firstly, the reported incidence rates
are based on passive notification and, therefore, cannot be
interpreted as an accurate reflection of the true incidence of
infection or disease in these populations. Secondly, in the
past 10 years, the immunisation rates in all countries except
for Estonia and Turkey have been over 95% and, thus,
minor improvements may have had barely any noticeable
influence on the incidence of disease. Thirdly, a closer look
at the Estonian data clearly demonstrates that, with the
improved primary immunisation coverage, the incidence of
pertussis in infancy has dropped. Finally, the primary
immunisation rates are unlikely to affect disease rates in
school-aged children or adults, since protection against
pertussis disease is not life-long.
Despite the likely under reporting, an increased inci-
dence of infant, adolescent and adult pertussis has been
observed worldwide, in spite of the widespread introduction
of vaccination programmes [14]. This is a cause of concern
because adolescents and adults have been identified as a
source of transmission of pertussis to very young infants
who have not been immunised or who are only partially
immunised, and, thus, more vulnerable to disease-related
complications and mortality. A few countries, including the
USA, Australia, Austria, Canada, France and Germany,
have incorporated an adolescent booster dose into their
immunisation schedules, in recognition of the changing age
distribution of pertussis infection [14].
In conclusion, on the basis of the currently available
epidemiologic data, it appears that there is a need for the
improved recognition, diagnosis and reporting of pertussis
in Central and Eastern European countries, in particular,
among older children and in adults. In view of the shift in
age-specific incidence rates towards older children and
adolescents in some CEEs, consideration should be given to
the incorporation of additional booster doses of pertussis
vaccine into national vaccination schedules. Our review has
provided useful insight about similarities between certain
countries with similar vaccination programmes, enabling
recommendations to be made on the basis of data generated
in countries with similar epidemiologies.
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